



“NASH Updates”



Na Li, M.D.

The Ohio State University
Wexner Medical Center

Recording, PowerPoint,
evaluation and posttest
Completion Time: 60 minutes
Release: 06/15/20
Termination: 06/15/2023

ENDURING MATERIAL From Virtual Conference

This enduring material activity is a recording from our “NASH Updates” CME conference presented by Na Li, M.D. from The Ohio State University Medical Center and focuses on **updates regarding NASH** or fatty liver disease.

Nonalcoholic fatty liver disease (or NAFLD) is a condition in which fat builds up in the liver. NASH (or nonalcoholic steatohepatitis) is a type of NAFLD that can damage the liver. NASH occurs when the fat buildup in the liver leads to inflammation (hepatitis) and scarring. NASH can be life-threatening, as it can cause liver scarring (called *cirrhosis*) or liver cancer. It is estimated that 3% to 5% of the global population is affected by NASH, though the disease is considered to be underdiagnosed.

OBJECTIVES:

At the conclusion of this conference, participants should be able to:

- Understand the clinical significance of NASH
- Identify high-risk patients with NASH and current diagnostic methods
- Review current treatment options for NASH and pharmacotherapies in the pipeline

Accreditation: Licking Memorial Hospital is accredited by the Ohio State Medical Association to provide continuing medical education for physicians.

Designation: Licking Memorial Hospital designates this **enduring material** activity for a maximum of **1 AMA PRA Category 1 Credit™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Speaker Disclosure: Dr. Na Li does not have any financial affiliations to disclose. The speaker will be using the best available published evidence to support their presentation and all scientific data references or used as justification of patient care recommendations conforms to the generally accepted standards of experimental design, data collection, and analysis. The speaker will use generic names for medications and or equipment to the best extent possible.

Planning Committee/Reviewers Disclosure: The following LMH planning committee members (and reviewers) have indicated that they have no relevant financial interest/arrangement with any organization(s) that could be perceived as having a direct bearing on the subject matter of this presentation: Craig Cairns, MD, Chair; Bashar Alawad, MD; Emilia Anigbo, MD; Audrey Bennett, MD; Garth Bennington, MD; Joseph Fondriest, MD; Rosita Frazier, M.D.; Frances Horenstein, MD; Timothy Lifer, DO; Henry Lu, MD; D’Anna Mullins, M.D.; Tiffany Owens, MD; David Subler, MD; Mary Torchia, MD; Elizabeth Yoder, DO; Jean Glaser, RPh, PharmD; Jeanne Emmons, Director of Infection Prevention; Nathan Adamson, Infection Prevention Manager; Kim Mathis, Patient Experience Manager; Kim Frick, P.I. Specialist; Lorei Reinhard, Director of Laboratory and Oncology Services; Stephen Gombos, M.T., Laboratory Manager; Jacqueline Evans, Director Revenue Cycle; Angela Wallace, Director of Surgical Services and Jessica Adamson, CME Coordinator. None of the planning committee members receives direct monetary benefit from the subject of this CME activity, nor are they personally compensated for their role. If any conflicts of interest pertaining to this activity were identified, they were resolved prior to the activity.